Kala Pharmaceuticals (KALA) Recently Broke Out Above the 200-Day Moving AverageZacks Investment Research • 03/22/23
Wall Street Bulls Look Optimistic About Kala Pharma (KALA): Should You Buy?Zacks Investment Research • 03/20/23
Kala Pharmaceuticals (KALA) Crossed Above the 50-Day Moving Average: What That Means for InvestorsZacks Investment Research • 03/09/23
Kala Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare ConferenceGlobeNewsWire • 03/08/23
How Much Upside is Left in Kala Pharma (KALA)? Wall Street Analysts Think 143.91%Zacks Investment Research • 03/08/23
Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/03/23
Wall Street Analysts Think Kala Pharma (KALA) Is a Good Investment: Is It?Zacks Investment Research • 03/02/23
Kala Pharmaceuticals (KALA) Flat As Market Sinks: What You Should KnowZacks Investment Research • 02/23/23
Kala Pharma: Rare Eye Disease Biotech Lottery Ticket Based On Stem Cell PlatformSeeking Alpha • 01/19/23
Kala Pharmaceuticals stock up 750% in 3 days after upbeat FDA news on PCED treatmentMarket Watch • 12/30/22
Wall Street Analysts Predict a 268% Upside in Kala Pharma (KALA): Here's What You Should KnowZacks Investment Research • 12/29/22
Kala Pharmaceuticals Stock Continues To Soar: What's Going On? - Kala Pharmaceuticals (NASDAQ:KALA)Benzinga • 12/29/22
Kala Pharmaceuticals stock rockets after FDA accepts IND application for PCED treatmentMarket Watch • 12/28/22
Kala Pharmaceuticals Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCEDGlobeNewsWire • 12/27/22
Kala Pharmaceuticals Announces Submission of Investigational New Drug Application for KPI-012 for the Treatment of Persistent Corneal Epithelial DefectGlobeNewsWire • 11/28/22